Latest News

Autolus Therapeutics aiming for NASDAQ IPO

This April, Autolus Therapeutics and Miltenyi Biotec inked a long-term agreement on the supply and support of Miltenyi Biotec’s CliniMACS Prodigy instruments, reagents and disposables for the manufacture of Autolus’ programmed T cell therapies. © Miltenyi Biotec


by tg

British T cell player, Autolus Therapeutics Ltd. wants to go NASDAQ selling 7.8 million American Depositary Shares (ADSs) at  at least US-$15, totaling in US$117m. Through a greenshoe option, Autolus want to offer additional 1,171,875 ADS at the IPO price. 

Goldman Sachs & Co. LLC and Jefferies LLC are acting as joint book-running managers for the offering. Wells Fargo Securities, LLC and William Blair & Company, L.L.C. are acting as lead managers.

The company is well-financed. Last September, Autolus added a US$80m Series C equity funding to US$96m raised in previous financing rounds led by Syncona Ltd., Woodford Investment Management, and Arix Bioscience plc.

Autolus‘ T cell therapies target the the blood cancer ALL either through CD19 (in Phase I) a similar approach to approved CAR-T cell therapies from Novartis and Gilead Sciences, or through targeting CD19 and CD22 (Phase I/II). The company's CD19 candidate however is claimed "next-generation" due to its fast CD19 dissociation kinetics, which allows to target many CD19+ cells very rapidly. Furthermore, the company’s CAR-T cells target CD269 and TACI to treat multiple myeloma (Phase I/II). An additional candidate undergoing Phase I safety testing targets GD2, a disialoganglioside expressed on tumours of neuroectodermal origin, to treat the rare childhood brain cancer neuroblastoma.

Researchers identify roots of childhood asthma

The discovery of a team headed by Hans Bisgaard at Gentofte Hospital in Gentofte, Denmark, reveals that childhood asthma is closely intertwined with...

IMI launches €45m call for coronavirus emergency

The funding is part of a €90m R&D finance package to fund the development of diagnostics and therapeutics withing public private partnerships of...

BIH scientists optimise CRISPR gene scissors

In Science Advances the team of Dr. Dominik Niopek at the University Hospital in Heidelberg and BioQuant Centre and Roland Eils at BIH Berlin present...

Valneva raises US$85m

Valneva said the transaction, led by US investors Deerfield Management Company and OrbiMed, included an initial US$60m fixed rate debt and flexible...

Nestlé heavily invests in sustainable packaging

According to the announcement and building on its 2018 commitment to make 100% of its packaging recyclable or reusable by 2025, Swiss food giant...

Sleeping sickness target deciphered

Using ultra-bright X-ray flashes, a team of researchers led by Lars Redecke from the University of Lübeck and DESY, Christian Betzel from the...

Mereo BioPharma raise money to back Phase III trials

Orphan drug specialist Mereo BioPharma Group plc (London) raised $5m from Novartis Pharma AG and  entered into a Securities Purchase Agreement...